High score of LDH plus dNLR predicts poor survival in patients with HER2-positive advanced breast cancer treated with trastuzumab emtansine

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1471-2407
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
High score of LDH plus dNLR predicts poor survival in patients with HER2-positive advanced breast cancer treated with trastuzumab emtansine ; volume:22 ; number:1 ; day:3 ; month:1 ; year:2022 ; pages:1-13 ; date:12.2022
BMC cancer ; 22, Heft 1 (3.1.2022), 1-13, 12.2022

Creator
Li, Liru
Ai, Lin
Jia, Lin
Zhang, Lei
Lei, Boya
Zhang, Qingyuan
Contributor
SpringerLink (Online service)

DOI
10.1186/s12885-021-09131-6
URN
urn:nbn:de:101:1-2022042120502610707494
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
15.08.2025, 7:20 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Li, Liru
  • Ai, Lin
  • Jia, Lin
  • Zhang, Lei
  • Lei, Boya
  • Zhang, Qingyuan
  • SpringerLink (Online service)

Other Objects (12)

Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer

Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer

Drug-induced thrombocytopenia associated with trastuzumab in a patient with HER2-positive recurrent gastric cancer

Drug-induced thrombocytopenia associated with trastuzumab in a patient with HER2-positive recurrent gastric cancer

NT-proBNP correlates with LVEF decline in HER2-positive breast cancer patients treated with trastuzumab

NT-proBNP correlates with LVEF decline in HER2-positive breast cancer patients treated with trastuzumab

Genetic mutations in HER2-positive breast cancer: possible association with response to trastuzumab therapy

Genetic mutations in HER2-positive breast cancer: possible association with response to trastuzumab therapy

Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer

Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer

Long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma

Long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma

Prognostic value of neutrophile-to-lymphocyte ratio (NLR) and lactate dehydrogenase (LDH) levels for geriatric patients with COVID-19

Prognostic value of neutrophile-to-lymphocyte ratio (NLR) and lactate dehydrogenase (LDH) levels for geriatric patients with COVID-19

Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer

Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer

Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer

Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer

CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer

CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer

Prognostic value of systemic inflammatory factors NLR, LMR, PLR and LDH in penile cancer

Prognostic value of systemic inflammatory factors NLR, LMR, PLR and LDH in penile cancer

Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2‑positive metastatic breast cancer

Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2‑positive metastatic breast cancer

Related objects